A RANDOMIZED PHASE III, TWO-ARM TRIAL OF PACLITAXEL/CARBOPLATIN/MAINTENANCE LETROZOLE VERSUS LETROZOLE MONOTHERAPY IN PATIENTS WITH STAGE II-IV, PRIMARY LOW-GRADE SEROUS CARCINOMA OF THE OVARY OR PERITONEUM
- Registry ID
- NRG-GY019
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NRG ONCOLOGY
- Start date
- 2021-03-29
- Last update
- 2020-06-22
Conditions
- FALLOPIAN TUBE CANCER
- OVARIAN CARCINOMA
- PERITONEAL CARCINOMA
Related clinical trials
- A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY
- A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF
IMGN151 (ANTI-FR¿ ANTIBODY-DRUG CONJUGATE) IN ADULT PATIENTS WITH RECURRENT
ENDOMETRIAL CANCER AND RECURRENT, HIGH-GRADE SEROUS EPITHELIAL OVARIAN,
PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS
- A PHASE 3 STUDY OF RELACORILANT IN COMBINATION WITH NAB-PACLITAXEL VERSUS NAB-PACLITAXEL MONOTHERAPY IN ADVANCED, PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN-TUBE CANCER (ROSELLA)
- RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE AS MAINTENANCE THERAPY FOR PATIENTS WITH FRA-HIGH RECURRENT PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCERS WHO HAVE NOT PROGRESSED AFTER SECOND-LINE PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB (GLORIOSA)
- MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF CARBOPLATIN PLUS MIRVETUXIMAB SORAVTANSINE FOLLOWED BY MIRVETUXIMAB SORAVTANSINE CONTINUATION IN FOLATE RECEPTOR-ALPHA POSITIVE, RECURRENT PLATINUM-SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS FOLLOWING 1 PRIOR LINE OF PLATINUM-BASED CHEMOTHERAPY
- ATR INHIBITOR IN COMBINATION WITH OLAPARIB/ DURVALUMAB (MEDI4736) IN GYNAECOLOGICAL CANCERS WITH ARID1A LOSS OR NO LOSS
View on source registry